TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B5946 EW-71971 CitationTarget: BMP and Other Activin ReceptorsSummary: Selective inhibitor of TGF-β type I receptor kinase
-
B5965 Tamoxifen1 CitationTarget: PKCSummary: TGF-β modulatory and PKC inhibitory effects
-
A3825 SLx-21191 CitationTarget: ROCKSummary: Selective ROCK2 inhibitor
-
A3133 A 83-01Summary: ALK-5 inhibitor
-
A8464 LY21097614 CitationSummary: TβRI/II kinase inhibitor
-
A8525 Sotrastaurin (AEB071)Target: PKCSummary: PKC inhibitor
-
A8604 GNF 5Target: Bcr-AblSummary: Bcr-Abl inhibitor
-
B2286 K02288Target: ALKSummary: ALK inhibitor
-
A3008 Y-27632 dihydrochloride19 CitationTarget: ROCKSummary: ROCK1 inhibitor
-
A8232 Nilotinib(AMN-107)1 CitationTarget: Bcr-AblSummary: Bcr-Abl kinase inhibitor,selective